JAVMA viewpoint questions 28 days of doxycycline for canine Lyme

VERSION 2 — FULL ANALYSIS

A new JAVMA viewpoint is asking a pointed clinical question: is 28 days of doxycycline still justified for canine Lyme arthropathy? The authors, Fiona Emdin, Nick Daneman, and J. Scott Weese, say the default month-long regimen has persisted largely by precedent, not because randomized evidence has shown it's the optimal duration. They argue there's now enough clinical equipoise to test a shorter, 10-day course in a randomized controlled trial. (pubmed.ncbi.nlm.nih.gov)

That argument cuts into a long-standing standard. The 2006 ACVIM consensus statement recommended doxycycline for one month in seropositive dogs with compatible clinical abnormalities, and the 2018 ACVIM update again said panelists agreed that Lyme arthritis be treated for four weeks, with doxycycline preferred. At the same time, the 2018 panel explicitly noted that the best drug, dosage, and duration for affected dogs are unknown, underscoring the evidence gap the JAVMA authors are now pressing on. CAPC guidance likewise continues to describe doxycycline at 10 mg/kg orally every 24 hours for 30 days as the standard treatment for disease caused by B. burgdorferi infection in dogs. (pubmed.ncbi.nlm.nih.gov)

The background matters because canine Lyme disease is often over-simplified in practice. The ACVIM update emphasizes that most naturally exposed dogs remain clinically normal despite seropositivity, and that proteinuria is uncommon among seropositive dogs. When clinical disease does occur, Lyme arthritis is the best-recognized syndrome, but the consensus statement also warns that lameness or proteinuria in a seropositive dog may be coincidental, with other tick-borne infections, immune-mediated disease, trauma, septic arthritis, or degenerative joint disease potentially explaining the presentation. It also notes that if relapse occurs before or after treatment, clinicians should broaden the differential diagnosis rather than assume persistent Lyme infection. (pmc.ncbi.nlm.nih.gov)

The evidence base for the 28-day norm is thinner than many clinicians might expect. Experimental work has evaluated antibiotic effects on Borrelia burden and serologic responses in dogs, including a study comparing cefovecin, doxycycline, and amoxicillin in experimentally induced early Lyme borreliosis. But even that work relied on surrogate markers because reliably inducing overt lameness in experimental dogs has been difficult. Earlier experimental data also suggested that antibiotic therapy reduced subsequent Borrelia positivity in skin biopsies, without definitively resolving the broader question of optimal clinical treatment duration for naturally occurring Lyme arthropathy. In other words, the field has supportive biologic data, but not the kind of randomized clinical trial the JAVMA viewpoint is calling for. (pmc.ncbi.nlm.nih.gov)

There is also a wider stewardship context behind the article. The ACVIM consensus statement on therapeutic antimicrobial use in animals notes that, across veterinary medicine, evidence guiding treatment duration is often limited and that shorter courses have proved effective for multiple human infectious syndromes. That doesn't mean human Lyme protocols can simply be imported into dogs, but it does help explain why the authors are asking whether "because we've always done 28 days" is still a sufficient rationale. Human Lyme guidelines still recommend 28 days of oral therapy for Lyme arthritis, showing that longer courses remain embedded in adjacent fields too, even as duration questions persist. (pmc.ncbi.nlm.nih.gov)

Expert and industry reaction appears limited so far, but the broader specialty literature already reflects the tension. Cornell's canine Lyme overview still states that Lyme disease is most commonly treated with doxycycline for four weeks, mirroring current practice. Meanwhile, Scott Weese, one of the viewpoint authors, has written separately about doxycycline use and resistance concerns, reinforcing that antimicrobial stewardship is a recurring theme in his work. That doesn't amount to a direct public reaction to the new viewpoint, but it does align with the article's central premise: standard practice should be revisited when evidence is thin and antibiotic exposure is substantial. (vet.cornell.edu)

Why it matters: For veterinarians, this is less about changing tomorrow's prescription than about re-examining the strength of today's evidence. A four-week doxycycline course remains the consensus-backed standard for suspected canine Lyme arthritis, and nothing in the viewpoint changes that immediately. But if a shorter course were shown to be noninferior in a well-designed trial, the downstream effects could be meaningful: less antibiotic exposure, fewer administration challenges for pet parents, lower cost, and a clearer stewardship case in a disease where seropositivity is common but true clinical illness is comparatively uncommon. It could also sharpen diagnostic discipline by forcing trials to define Lyme arthropathy more rigorously than it often is in everyday practice. (pmc.ncbi.nlm.nih.gov)

What to watch: The next step is whether investigators actually launch the randomized controlled trial the authors are proposing, and whether future ACVIM, CAPC, or other guideline updates begin to distinguish more clearly between historical convention and evidence-based duration recommendations for canine Lyme arthropathy. (pmc.ncbi.nlm.nih.gov)